Cyclone Metals Limited (ASX: CLE) has released its Quarterly Activities Report for the period ending 30 June 2025, and the momentum behind the Iron Bear Project is evident. Backed by a strategic partnership with Vale S.A., the quarter saw the completion of critical technical studies, advancement in metallurgical testing, progress across engineering and environmental baselines, and tangible steps toward the upcoming Scoping Study and PFS.

AML3D Limited (ASX: AL3) continues to solidify its reputation as a key enabler of defence manufacturing transformation. Over the June 2025 quarter, the company advanced its “US Scale Up” strategy with concrete progress in strategic partnerships, facility expansion, and order momentum. With a freshly announced order for a portable ARCEMY® system and a strong quarterly cash position of A$30.4 million, AML3D is not just building metal parts, but reshaping how defence manufacturi

Proteomics International Laboratories Ltd (ASX: PIQ), a recognised pioneer in precision diagnostics, has announced a significant development for the Western Australian scientific and medical landscape: a $6 million funding boost to expand the WA Proteomics Facility. This strategic investment will be delivered over three years, with contributions from the WA State Government, Bioplatforms Australia, the University of Western Australia (UWA), and Proteomics International itself

Ausgold Limited (ASX: AUC) has delivered a definitive milestone with the release of its Definitive Feasibility Study (DFS) for the 100%-owned Katanning Gold Project (KGP). The study validates KGP as one of Australia’s most advanced undeveloped open-pit gold projects, combining scale, near-term development potential, and robust economics within a Tier-1 jurisdiction

Mesoblast Limited (ASX: MSB | Nasdaq: MESO) has taken a critical step toward commercialising its lead cardiac product candidate, Revascor® (rexlemestrocel-L), with formal alignment reached with the United States Food and Drug Administration (FDA) on the key requirements for filing a Biologics License Application (BLA) in the treatment of ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has taken a major strategic step by acquiring StemSmart™, a globally patented and clinically validated stem cell platform. This acquisition adds a powerful, next-generation therapeutic capability to the company’s focus on neuroimmune and inflammatory diseases.

30 June 2025 – Lightning Minerals Ltd (ASX: L1M) has announced a transformational acquisition of two advanced brownfields projects targeting gold and copper in Queensland  (Mt Turner Projects) and New South Wales (Lachlan Fold Copper Porphyry Project). The acquisition of Lotus Minerals Pty Ltd significantly strengthens the Company’s portfolio and introduces immediate drill targets in some of Australia’s most mineral-endowed regions.

OpenLearning Limited (ASX: OLL) has secured two strategic SaaS agreements in quick succession, expanding its reach in both Southeast Asia and Australia. The first, a A$495,000 deal with CE-Logic Inc. in the Philippines and a 5-year A$155,000 agreement with the Education Centre of Australia. Together, these wins underscore OpenLearning’s growing momentum across key education markets.

Wide Open Agriculture Ltd (ASX: WOA) has announced a major technical milestone with the successful completion of a commercial-scale manufacturing trial of its proprietary lupin protein isolate process (BP80F), conducted in the United States. Samso has previously covered WOA's journey in lupin-based innovation, and this latest update continues that narrative of disciplined progress and technical refinement.

RareX Limited (ASX: REE) has delivered another round of eye-catching assay results that significantly strengthen its position as the developer of one of Australia's most advanced and highest-grade gallium deposits at the Cummins Range Project (Figure 1). The latest update, announced on 24 June 2025, showcases high-grade gallium re-assays from Cummins Range and builds upon an already compelling narrative that began with RareX’s March 2025 discovery announcement.